Overview

Clofazimine- and Rifapentine-Containing Treatment Shortening Regimens in Drug-Susceptible Tuberculosis: The CLO-FAST Study

Status:
Recruiting

Trial end date:
2022-11-18

Target enrollment:

Participant gender:

Summary

The purpose of this study is to compare a 3-month rifapentine (RPT)/clofazimine (CFZ)-containing regimen with CFZ loading dose versus 6-month standard of care (SOC) for drug-susceptible (DS) tuberculosis (TB).

Phase:

Phase 2

Details

Lead Sponsor:

National Institute of Allergy and Infectious Diseases (NIAID)

Treatments:

Clofazimine
Ethambutol
Isoniazid
Pyrazinamide
Pyridoxal
Pyridoxine
Rifampin
Rifapentine
Vitamin B 6
Vitamin B Complex
Vitamins